US FDA announces hike in PDUFA user fee rates for FY 2012
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration is to increase the fee it charges for reviewing drug applications that require clinical data by 19.4% to $1.8 million, the agency revealed in a Federal Register notice of its new prescription drug user fee rates for fiscal year 20121.
You may also be interested in...
Pakistan Explains Updated Risk-Based Criteria For GCP Inspections
Pakistan’s drug regulator is hoping that improved transparency on its inspection protocols will help research entities better prepare for good clinical practice inspections.
UK MHRA Inspector Highlights Mistakes Made In Decentralized Clinical Trials
Inadequate risk assessments, participant confidentiality breaches and issues with documenting and verifying clinical trial activities have emerged as recurring themes in inspections of decentralized clinical trials by the UK medicines regulator.
UK, US & Canada Regulators Explain Why Decentralized Trials May Get A Closer Look
Decentralized clinical trials are subject to the same regulatory requirements as traditional site-based trials, but are of special interest to regulators because they represent a new way of working.